Switch theme
Sign up to access all valuation multiples
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
2005
14.9K+
LTM Revenue $13.3B
LTM EBITDA $2.6B
$43.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Daiichi Sankyo has a last 12-month revenue of $13.3B and a last 12-month EBITDA of $2.6B.
In the most recent fiscal year, Daiichi Sankyo achieved revenue of $11.2B and an EBITDA of $2.1B.
Daiichi Sankyo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Daiichi Sankyo valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $7.3B | $8.9B | XXX | XXX | XXX |
| Gross Profit | $4.8B | $6.4B | XXX | XXX | XXX |
| Gross Margin | 66% | 72% | XXX | XXX | XXX |
| EBITDA | $962M | $1.4B | XXX | XXX | XXX |
| EBITDA Margin | 13% | 16% | XXX | XXX | XXX |
| Net Profit | $469M | $764M | XXX | XXX | XXX |
| Net Margin | 6% | 9% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 1, 2025, Daiichi Sankyo's stock price is JPY 3644 (or $26).
Daiichi Sankyo has current market cap of JPY 6.81T (or $47.7B), and EV of JPY 6.19T (or $43.3B).
See Daiichi Sankyo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43.3B | $47.7B | XXX | XXX | XXX | XXX | $1.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 1, 2025, Daiichi Sankyo has market cap of $47.7B and EV of $43.3B.
Daiichi Sankyo's trades at 3.3x LTM EV/Revenue multiple, and 16.7x LTM EBITDA.
Analysts estimate Daiichi Sankyo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Daiichi Sankyo and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $43.3B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 22.3x | XXX | XXX | XXX |
| P/E | 38.3x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | 16.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDaiichi Sankyo's NTM/LTM revenue growth is 11%
Daiichi Sankyo's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Daiichi Sankyo's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Daiichi Sankyo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Daiichi Sankyo and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 48% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 40% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 61% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daiichi Sankyo acquired XXX companies to date.
Last acquisition by Daiichi Sankyo was XXXXXXXX, XXXXX XXXXX XXXXXX . Daiichi Sankyo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Daiichi Sankyo founded? | Daiichi Sankyo was founded in 2005. |
| Where is Daiichi Sankyo headquartered? | Daiichi Sankyo is headquartered in Japan. |
| How many employees does Daiichi Sankyo have? | As of today, Daiichi Sankyo has 14.9K+ employees. |
| Who is the CEO of Daiichi Sankyo? | Daiichi Sankyo's CEO is Mr. Sunao Manabe. |
| Is Daiichi Sankyo publicy listed? | Yes, Daiichi Sankyo is a public company listed on TKS. |
| What is the stock symbol of Daiichi Sankyo? | Daiichi Sankyo trades under 4568 ticker. |
| When did Daiichi Sankyo go public? | Daiichi Sankyo went public in 2005. |
| Who are competitors of Daiichi Sankyo? | Similar companies to Daiichi Sankyo include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Daiichi Sankyo? | Daiichi Sankyo's current market cap is $47.7B |
| What is the current revenue of Daiichi Sankyo? | Daiichi Sankyo's last 12-month revenue is $13.3B. |
| What is the current EBITDA of Daiichi Sankyo? | Daiichi Sankyo's last 12-month EBITDA is $2.6B. |
| What is the current EV/Revenue multiple of Daiichi Sankyo? | Current revenue multiple of Daiichi Sankyo is 3.3x. |
| What is the current EV/EBITDA multiple of Daiichi Sankyo? | Current EBITDA multiple of Daiichi Sankyo is 16.7x. |
| What is the current revenue growth of Daiichi Sankyo? | Daiichi Sankyo revenue growth between 2023 and 2024 was 22%. |
| Is Daiichi Sankyo profitable? | Yes, Daiichi Sankyo is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
